Gang Chen

US Patent:

7065285, Jun 20, 2006

Filed:

Dec 1, 2003

Appl. No.:

10/724174

Inventors:

Gang Chen - New Providence NJ, US
Dan Fuchs - Summit NJ, US
Ylva Olsson - New Providence NJ, US
Ronen Rapaport - Chatham NJ, US
Vikram Sundar - Millwood NY, US

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

G02B 6/00

US Classification:

385141, 385142, 385143

Abstract:

The present invention relates to a polymeric composition of matter. The composition includes at least one polymer matrix and plurality of quantum dots distributed therein. The polymer may be a perfluorocyclobutane polymer having high optical transmission at telecommunications wavelengths. The quantum dots may include cap compounds to increase the solubility of the quantum dots in the composition. Typical cap compounds include aromatic organic molecules. Optical devices including waveguides may be fabricated from the polymeric compositions of the invention.

US Patent:

7168266, Jan 30, 2007

Filed:

Mar 6, 2003

Appl. No.:

10/383150

Inventors:

Gang Chen - New Providence NJ, US
Ronen Rapaport - Chatham NJ, US
Elsa Reichmanis - Westfield NJ, US
Shu Yang - North Plainfield NJ, US

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

C03B 19/12

US Classification:

65 172, 65 23, 65 31, 20415741, 20415761, 264628

Abstract:

Techniques for producing a glass structure having interconnected macroscopic pores, employing steps of filling polymerizable glass precursors into pores in a polymeric structure having interconnected macroscopic pores; polymerizing the precursors; and decomposing the polymers to produce a glass oxide structure having interconnected macroscopic pores. Further techniques employ steps of exposing portions of a photosensitive medium including glass precursors to an optical interference pattern; polymerizing or photodeprotecting the exposed portions and removing unpolymerized or deprotected portions; and decomposing the polymerized or deprotected portions to produce a glass structure having interconnected macroscopic pores. Techniques for filling pores of such glass structure with a material having a high refractive index, and for then removing the glass structure. Structures can be produced having interconnected macroscopic pores and high refractive index contrasts, which can be used, for example, as photonic band gaps.

US Patent:

7197226, Mar 27, 2007

Filed:

Apr 11, 2006

Appl. No.:

11/402693

Inventors:

Gang Chen - New Providence NJ, US
Dan Fuchs - Summit NJ, US
Ylva Olsson - New Providence NJ, US
Ronen Rapaport - Chatham NJ, US
Vikram Sundar - Millwood NY, US

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

G02B 6/00

US Classification:

385141, 385142, 385143

Abstract:

The present invention relates to a polymeric composition of matter. The composition includes at least one polymer matrix and plurality of quantum dots distributed therein. The polymer may be a perfluorocyclobutane polymer having high optical transmission at telecommunications wavelengths. The quantum dots may include cap compounds to increase the solubility of the quantum dots in the composition. Typical cap compounds include aromatic organic molecules. Optical devices including waveguides may be fabricated from the polymeric compositions of the invention.

US Patent:

7457508, Nov 25, 2008

Filed:

Jan 8, 2007

Appl. No.:

11/650668

Inventors:

Gang Chen - New Providence NJ, US
Dan Fuchs - Summit NJ, US
Ylva Olsson - New Providence NJ, US
Ronen Rapaport - Chatham NJ, US
Vikram Sundar - Millwood NY, US

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

G02B 6/00

US Classification:

385141, 385143

Abstract:

The present invention relates to a polymeric composition of matter. The composition includes at least one polymer matrix and plurality of quantum dots distributed therein. The polymer may be a perfluorocyclobutane polymer having high optical transmission at telecommunications wavelengths. The quantum dots may include cap compounds to increase the solubility of the quantum dots in the composition. Typical cap compounds include aromatic organic molecules. Optical devices including waveguides may be fabricated from the polymeric compositions of the invention.

US Patent:

7570864, Aug 4, 2009

Filed:

Sep 26, 2008

Appl. No.:

12/284972

Inventors:

Gang Chen - New Providence NJ, US
Dan Fuchs - Summit NJ, US
Ylva Olsson - New Providence NJ, US
Ronen Rapaport - Chatham NJ, US
Vikram Sundar - Millwood NY, US

Assignee:

Alcatel-Lucent USA Inc. - Murray Hill NJ

International Classification:

G02B 6/00

US Classification:

385141, 385142, 385143

Abstract:

The present invention relates to a polymeric composition of matter. The composition includes at least one polymer matrix and plurality of quantum dots distributed therein. The polymer may be a perfluorocyclobutane polymer having high optical transmission at telecommunications wavelengths. The quantum dots may include cap compounds to increase the solubility of the quantum dots in the composition. Typical cap compounds include aromatic organic molecules. Optical devices including waveguides may be fabricated from the polymeric compositions of the invention.

US Patent:

7582298, Sep 1, 2009

Filed:

Jun 1, 2007

Appl. No.:

11/809482

Inventors:

Sean Stevens - Mohegan Lake NY, US
Tammy T. Huang - Golden Bridge NY, US
Joel H. Martin - Putnam Valley NY, US
Jeanette L. Fairhurst - White Plains NY, US
Ashique Rafique - Yonkers NY, US
Eric Smith - New York NY, US
Kevin J. Pobursky - Beacon NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
James P. Fandl - LaGrangeville NY, US
Gang Chen - Yorktown Heights NY, US
Margaret Karow - Camarillo CA, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C07K 16/28
A61K 39/395

US Classification:

4241431, 5303879, 53038822

Abstract:

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a Kof about 500 pM or less and blocks IL-6 activity with an ICof 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

US Patent:

7771997, Aug 10, 2010

Filed:

Jun 4, 2008

Appl. No.:

12/132846

Inventors:

Gang Chen - Yorktown Heights NY, US
Robert Babb - Nauet NY, US
James P. Fandl - LaGrangeville NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 5/10

US Classification:

435358, 435 691, 435367

Abstract:

Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.

US Patent:

8080248, Dec 20, 2011

Filed:

May 14, 2010

Appl. No.:

12/780006

Inventors:

Allen Radin - New York NY, US
Sean Stevens - San Diego CA, US
Tammy T. Huang - Goldens Bridge NY, US
Joel H. Martin - Putnam Valley NY, US
Jeanette L. Fairhurst - White Plains NY, US
Ashique Rafique - Yonkers NY, US
Eric Smith - New York NY, US
Kevin J. Pobursky - Beacon NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
James P. Fandl - LaGrangeville NY, US
Gang Chen - Yorktown Heights NY, US
Margaret Karow - Camarillo CA, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/395

US Classification:

4241431, 4241301, 4241411, 4241421, 4241441, 514885

Abstract:

The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.